Malcolm C. Pike , Ph.D.

Research Interests

Dr. Pike's main research interest is the chemoprevention of female cancers by a hormonal contraceptive approach. He also has major interests in the effects of hormone replacement therapy on breast and endometrial cancer, and in the diet on female cancer risk.

Degrees

Aberdeen University, UK, PHD, 1963

Professional Experience

Scientific Staff, Medical Research Council's Statistical Research Unit, London, England., 1963 - 1969
First Assistant, Regius Department of Medicine, University of Oxford, Oxford, England., 1969 - 1973
Professor of Preventive Medicine, University of Southern California, Los Angeles, California, USA., 1973 - 1983
Director, ICRF Cancer Epidemiology Unit, University of Oxford, Oxford, England., 1983 - 1987
Professor of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California, USA., 1987 - 1989
Professor & Chairman, Preventive Medicine, University of Southern California, Los Angeles, California, USA., 1989 - 1999
Flora L. Thornton Chairman of Preventive Medicine, University of Southern California, Los Angeles, California, USA., 1994 - 1999

Awards

Guy Medal (Bronze) of Royal Statistical Society. , 1968
Brinker International Award of the Susan G. Komen Breast Cancer Foundation. , 1994
USC Associates Award for Creativity in Research. , 1996

Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 1983;303:767-770.

Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749-756.

Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983;ii:926-930.

Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chron Dis 1987;40(Suppl. 2):59S-69S.

Key TJA, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988;24:29-43.

Key TJA, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-212.

Pike MC, Ross RK, Lobo RA, Key TJA, Potts M, Henderson BE. LHRH agonists and the prevention of breast and ovarian cancer. Br J Cancer 1989;60:142-148.

UK National Case-Control Study Group ( Pike MC, Principal Investigator). Oral contraceptive use and breast cancer risk in young women. Lancet 1989;ii:973-982.

Key TJA, Chen J, Wang DY, Pike MC, Boreham J. Sex hormones in women in rural China and in Britain. Br J Cancer 1990;62:631-636.

Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-436.

Eaton SB, Pike MC, Short RV, Lee NC, Trussell J, Hatcher RA, Wood JW, Worthman CM, Blurton Jones NG, Konner MJ, Hill KR, Bailey R, Hurtado AM. Women's reproductive cancers in evolutionary context. Q Rev Biol 1994;69:353-367.

Wu AH, Ziegler RG, Horn-Ross PL, Nomura AMY, West DW, Kolonel LN, Rosenthal JF, Hoover RN, Pike MC. Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol Biomark Prev 1996;5:901-906.

Pike MC, Daniels JR, Spicer DV. A hormonal contraceptive approach to reducing breast and ovarian cancer risk: an update. Endocrine-Related Cancer 1997;4:125-133.

Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116.

Swerdlow AJ, Higgins CD, Pike MC. Risk of testicular cancer in a cohort of boys with cryptorchidism. Br Med J 1997;314:1507-1511.

Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17a gene CYP17 polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-587.

Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Yu MC, Feigleson H, Stanczyk FZ, Kolonel LN, Henderson BE. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-4504.

Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 1998;147:718-721.

Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JKV. A missense substitution in the SRD5A2 gene is associated with prostate cancer in African-American and Hispanic men in Los Angeles. Lancet 1999;354: 975-978.

Wu AH, Pike MC, Stram DO. Meta-analysis: Dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 1999;91:529-534.

Feigelson HS, McKean-Cowdin R, Pike MC, Coetzee GA, Kolonel LN, Nomura AMY, Le Marchand LL, Henderson BE. Cytochrome P450c17a gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res 1999;59:3908-3910.

Zheng W, Luo F, Lu JJ, Baltayan A, Press MF, Zhang Z-F, Pike MC. Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol 2000;76:294-300.

Zheng W, Lu JJ, Luo F, Zheng Y, Feng Y-j, Lauchlan SC, Pike MC. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 1999;76:80-88.

Ross RK, Paganini-Hill A, Wan PC, Pike MC. Estrogen versus estrogen-progestin hormone replacement therapy: effect on breast cancer risk. J Natl Cancer Inst 2000;92:328-332.

Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer.

Stram DO, Hankin JH, Wilkens LR, Pike MC, Monroe KR, Park S, Henderson BE, Nomura AMY, Earle ME, Nagamine FS, Kolonel LN. Calibration of the dietary questionnaire for a Multiethnic Cohort in Hawaii and Los Angeles. Am J Epidemiol 2000;151:358-370.